Glial-neurotrophic mechanisms in Down syndrome

Journal of Neural Transmission, Supplement

Volumn , Issue 61, 2001, Pages 85-94

  Nelson, P G ^a,d   McCune, S K ^b   Ades, A M ^b   Nelson, K B ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REGULATOR PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE; ACETYLCHOLINE;

ARTICLE; BRAIN CORTEX; CELL ACTIVITY; CELL SURVIVAL; CHOLINERGIC NERVE; CHOLINERGIC NERVE CELL; DOWN SYNDROME; ELECTRIC ACTIVITY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GLIA; HUMAN; MOLECULAR DYNAMICS; NERVE CELL; NERVE CELL EXCITABILITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; ANIMAL; CELL COMMUNICATION; PATHOLOGY; PHYSIOLOGY; REVIEW;

ACETYLCHOLINE; ANIMAL; CELL COMMUNICATION; DOWN SYNDROME; HUMAN; NEUROGLIA; NEURONS;

EID: 0035226479     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6262-0_7     Document Type: Article

References (43)

1. Ades AM, McCune SK, Crnic LS, Ring M, Brenneman DE, HiLL JM (2000) Vasoactive intestinal peptide dysfunction associated with a segmental trisomy model of Down syndrome [Abstract]. Soc Ped Res 79: 472
2. Bambrick LL, Golovina VA, Blaustein MP, Yarowsky PJ, Krueger BK (1997) Abnormal calcium homeostasis in astrocytes from the trisomy 16 mouse. Glia 19: 352-358
3. Bear MF, Singer W (1986) Modulation of visual cortical plasticity by acetylcholine and noradrenaline. Nature 320: 172-176
4. Blondel O, Collin C, McCarran B, Zhu X, Zamostiano R, Gozes I, Brenneman DE, McKay R (2000) A glia-derived signal regulating neuronal differentiation. J Neurosci 20: 8012-8020
5. Brenneman DE (1986) Role of electrical activity and trophic factors during cholinergic development in dissociated cultures. Can J Physiol Pharmacol 64: 356-362
6. Brenneman DE, Yu C, Nelson PG (1990) Multi-determinate regulation of neuronal survival: neuropeptides, excitatory amino acids and bioelectric activity. Int J Dev Neurosci 8: 371-378
7. Brenneman DE, Hill JM, Glazner GW, Gozes I, Phillips TM (1995) Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int J Dew Neurosci 13: 187-200
8. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB (1998) Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335: 639-642
9. Brenneman DE, Hauser J, Phillips TM, Davidson A, Bassan M, Gozes I (1999) Vasoactive intestinal peptide: link between electrical activity and glia mediated neurotrophism. Ann NY Acad Sci 897: 17-26
10. Brown R (2000) Neuronal release of vasoactive intestinal peptide is important to astrocyte protection of neurons from glutamate toxicity. Mol Cell Neurosci 15: 465-475
11. Caserta MT (1994) Neuropeptide Y immunoreactive neurons in murine trisomy 16 cortical cultures. Plasticity of expression and differentiation Mol. Chem Neuropathol 22: 197-210
12. Davisson MT, Schmidt C, Reeves RH, Irving NG, Akeson EC, Harris BS, Bronson RT (1993) Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res 384: 117-133
13. de la Monte SM (1999) Molecular abnormalities of the brain in Down syndrome, relevance to Alzheimer's neurodegeneration. J Neural Transm [Suppl] 57: 1-19
14. Delcroix JD, Cooper JD, Howe CL, Belichenko PV, Valleta JS, Lee AAT, Mobley WC (1999) Failure of axonal retrograde 1251-NGF transport by septal neurons in a mouse model of Down syndrome. J Neurosci 19: 523-527
15. Ford KA, Granholm ARE, Crnic LS, Hyde LA, Seo H, Ferree AW, Isacson O (2000) Alterations in APP and NGF levels in an animal model of Down syndrome. Neurosci Abstr 76: 421
16. Glazner G, Gressens P, Lee SJ, Gibney G, Gozes I, Gozes Y, Brenneman DE, Hill JM (1999) Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. Anat Embryol 200: 65-71
17. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M (2001) Immunology of VIP: a review and theapeutical perspectives. Curr Pharm Des 7: 89-111
18. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci 93: 427-432
19. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E (1997) Protection against developmental retardation in apolipoprotein E deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J Neurobiol 33: 329-342
20. Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E et al. (1999) A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann NY Acad Sci 897: 125-135
21. Granholm ARE, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down syndrome. Exp Neurol 161: 647-663
22. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P (1997) Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 100: 390-397
23. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mark RE (1998) Glial-neuronl Interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 8: 65-72
24. Gu Q, Singer W (1989) The role of muscarinic receptors in ocular dominance plasticity. EXS 57: 305-314
25. Hohmann CF, Berger-Sweeney J (1998) Cholinergic regulation of cortical development and plasticity, new twists to an old story. Persp Dev Neurobiol 5: 401-425
26. Holtzman DM, Kilbridge J, Chen K, Rabin J, Luche R, Carlson E, Epstein CJ, Mobley WC (1995) Preliminary characterization of the central nervous system in partial trisomy 16 mice. Prog Clin Biol Res 393: 227-240
27. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci 93: 13333-13338
28. Insausti AM, Megias M, Crespo D, Cruz-Orive LM, Dierssen M, Vallina TF, Insausti R, Florez J (1998) Hippocampal volume and neuronal number in mice: a murine model of Down syndrome. Neurosci Lett 253: 175-178
29. Kalfin R, Maulik N, Engelman RM, Cordis GA, Milenov K, Kasakov L, Das DK (1994) Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium. J Pharmacol Exp Ther 268: 953-958
30. Korsching S, Thoenen H (1983) Quantitative demonstration of the retrograde axonal transport of endogenous nerve growth factor, Neurosci Lett 39: 1-4
31. Krnjevic K, Pumain R, Renaud L (1971) The mechanism of exccitation by acetylcholine in the cerebral cortex. J Physiol 215: 247-268
32. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J (1999) Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 93: 126-138
33. Muller W, Heinemann U, Schuchmann S (1997) Impaired Ca-signaling in astrocytes from the Ts16 mouse model of Down syndrome. Neurosci Lett 223: 81-84
34. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM (2001) Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49: 597-606
35. Nelson PG, Fitzgerald S, Rapoport SI, Neale EA, Galdzicki Z, Dunlap V, Bowers L, van Agoston (1997) Cerrebral cortical astroglia from the trisomy 16 mouse, a model for Down syndrome, produce neuronal cholinergic deficits in cell culture. Proc Natl Acad Sci 94: 12644-12648
36. Pitts RL, Wang S, Jones EA, Symes AJ (2001) Transforming growth factor beta and ciliary neurotrophic factor synergisticlly induce vasoactive intestinal peptide gene expression through the cooperation of Smad, Stat and AP-1 sites. J Biol Chem (Epublication ahead of print)
37. Richtsmeier JT, Baxter LL, Reeves RH (2000) Parallels of craniofacial caldevelopment in Down syndrome and Ts65Dn mice. Dev Dynam 17: 137-145
38. Schwartz JP, Mishler K (1990) Beta-adrenergic receptor regulation, through cyclic AMP, of nerve growth factor expression in rat cortical and cerebellar strocytes. Cell Mol Neurobiol 10: 447-457
39. Seiler M, Schwab ME (1984) Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res 300: 33-39
40. Spong C, Abebe DT, Gozes I, Brenneman DE, Hill JM (2001) Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 297: 774-779
41. Symes AJ, Pitts RL, Conover J, Kos K, Coulombre J (2000) Synergy of activin and ciliary neurotrophic factor signaling pathways in the induction of vasoactive intestinal peptide gene expression. Mol Endocrinol 14: 429-439
42. Ure DR, Campenot RB (1994) Leukemia inhibitory factor and nerve growth factor are retrogratedly transported and processed by cultured rat sympathetic neurons. Dev Biol 162: 339-347
43. Wang S, Rosengren LE, Franlund M, Hamberger A, Haglid KG (1999) Bcl 2 expression regulates cell sensitivity to S100-b mediated apoptosis. Brain Res Mol Brain Res 0: 167-176